Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AADAT | Q8N5Z0 | 2/20 | 0.52 |
| ▸ | PREP | P48147 | 3/20 | 0.48 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.48 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL953138 | 1.00 | AADAT (0.52) | AADATPREPTMEM97SIGMAR1ACE2 | |
| SCHEMBL18850754 | 0.87 | HCRTR1 (0.53) | AADATPREPTMEM97SIGMAR1ACE2 | |
| SCHEMBL475406 | 0.86 | AADAT (0.51) | AADATPREPTMEM97SIGMAR1ACE2 | |
| SCHEMBL475407 | 0.86 | AADAT (0.51) | AADATPREPTMEM97SIGMAR1ACE2 | |
| SCHEMBL27908484 | 0.86 | AADAT (0.51) | AADATPREPTMEM97SIGMAR1ACE2 | |
| SCHEMBL27891373 | 0.86 | AADAT (0.51) | AADATPREPTMEM97SIGMAR1ACE2 | |
| SCHEMBL27891374 | 0.85 | AADAT (0.49) | AADATPREPTMEM97SIGMAR1ACE2 | |
| SCHEMBL952907 | 0.83 | PREP (0.50) | AADATPREPTMEM97SIGMAR1ACE2 | |
| SCHEMBL952909 | 0.83 | PREP (0.50) | AADATPREPTMEM97SIGMAR1ACE2 | |
| SCHEMBL673184 | 0.81 | PRCP (0.56) | AADATTMEM97SIGMAR1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426420-B2 | Heterocyclic pyrazole-carboxamidesas P2Y12 antagonists | SANOFI (FR) | 2013-04-23 | — | — | US | disclosed |
| EP-2238128-B1 | HETEROCYCLIC PYRAZOLE-CARBOXAMIDES AS P2Y12 ANTAGONISTS | SANOFI SA (FR) | 2012-08-22 | — | — | EP | disclosed |
| US-20110021537-A1 | HETEROCYCLIC PYRAZOLE-CARBOXAMIDESAS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2011-01-27 | — | — | US | disclosed |
| EP-2238128-A2 | HETEROCYCLIC PYRAZOLE-CARBOXAMIDES AS P2Y12 ANTAGONISTS | Sanofi-Aventis (FR) | 2010-10-13 | — | — | EP | disclosed |
| WO-2009080226-A2 | HETEROCYCLIC PYRAZOLE-CARBOXAMIDES AS P2Y12 ANTAGONISTS | SANOFIS-AVENTIS (FR) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021537-A1 | HETEROCYCLIC PYRAZOLE-CARBOXAMIDESAS P2Y12 ANTAGONISTS | P2RY1, P2RY12, P2RY11 | AADAT 1577/4885PREP 2030/4885TMEM97 326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.